Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Decade in review—multiple sclerosis

New drugs and personalized medicine for multiple sclerosis

The past decade of multiple sclerosis research has been marked by important advances in understanding the disease, a dramatic increase in the range of treatment options and a new spirit of data sharing in research for patient benefit. This progress has made personalized medicine in multiple sclerosis a realistic possibility.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Hauser, S. L. et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N. Engl. J. Med. 358, 676–688 (2008).

    CAS  Article  Google Scholar 

  2. Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337–341 (2015).

    CAS  Article  Google Scholar 

  3. International Multiple Sclerosis Genetics Consortium et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214–219 (2011).

  4. Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S. & Hinson, S. R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202, 473–477 (2005).

    CAS  Article  Google Scholar 

  5. Tobin, W. O., Weinshenker, B. G. & Lucchinetti, C. F. Longitudinally extensive transverse myelitis. Curr. Opin. Neurol. 27, 279–289 (2014).

    Article  Google Scholar 

  6. Coles, A. J. et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380, 1829–1839 (2012).

    CAS  Article  Google Scholar 

  7. Chataway, J. et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383, 2213–2221 (2014).

    CAS  Article  Google Scholar 

  8. Multiple Sclerosis Discovery Forum [online] (2015).

  9. Bloomgren, G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870–1880 (2012).

    CAS  Article  Google Scholar 

  10. Palace, J. et al. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurol. 14, 497–505 (2015).

    Article  Google Scholar 

Download references

Acknowledgements

The author gratefully acknowledges personal support from the Edmond Safra Foundation and Lily Safra, the Imperial College Healthcare Trust Biomedical Research Centre, and as an NIHR Senior Investigator.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul M. Matthews.

Ethics declarations

Competing interests

The author has received funding for his research from GlaxoSmithKline and Biogen. The author has received speaker's fees or honoraria paid to his institution from Adelphi Communications, Biogen, IXICO, GlaxoSmithKline and Novartis.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Matthews, P. New drugs and personalized medicine for multiple sclerosis. Nat Rev Neurol 11, 614–616 (2015). https://doi.org/10.1038/nrneurol.2015.200

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2015.200

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing